Liver International
Displaying 1 - 5 of 5
Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2024). The first MASH drug therapy on the horizon: Current perspectives of resmetirom. Liver International, 44(7), 1526–1536. Portico. https://doi.org/10.1111/liv.15930
Publication Date
Columbia Affiliation
Yang, W., Ebrahimi, F., Romeo, S., Holmer, M., Vessby, J., Ekstedt, M., Ludvigsson, J. F., Shang, Y., & Hagström, H. (2024). Risk of major adverse liver outcomes among first‐degree relatives of individuals with MASLD. Liver International, 44(5), 1253–1264. Portico. https://doi.org/10.1111/liv.15874
Publication Date
Columbia Affiliation
Ebrahimi, F., Simon, T. G., Hagström, H., Sun, J., Bergman, D., Forss, A., Roelstraete, B., Engstrand, L., & Ludvigsson, J. F. (2023). Antibiotic use and development of nonalcoholic fatty liver disease: A population‐based case–control study. Liver International, 43(10), 2186–2197. Portico. https://doi.org/10.1111/liv.15663
Publication Date
Columbia Affiliation
Shang, Y., Widman, L., Ebrahimi, F., Ludvigsson, J. F., Hagström, H., & Wester, A. (2023). Risk of infections in non‐alcoholic fatty liver disease: A nationwide population‐based cohort study. Liver International, 43(10), 2142–2152. Portico. https://doi.org/10.1111/liv.15680
Publication Date
Columbia Affiliation
Jiménez, C., Ventura‐Cots, M., Sala, M., Calafat, M., Garcia‐Retortillo, M., Cirera, I., Cañete, N., Soriano, G., Poca, M., Simón‐Talero, M., Altamirano, J., Lucey, M., Garcia‐Tsao, G., Brown, R. S., Schwabe, R. F., Verna, E. C., Schnabl, B., Bosques‐Padilla, F., Mathurin, P., … Vargas, V. (2022). Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH). Liver International, 42(5), 1109–1120. Portico. https://doi.org/10.1111/liv.15207
Publication Date
Columbia Affiliation